Stonebridge Herald has published a detailed report examining the FDA's September 17, 2026 approval of Fayuvi (rebisufligene etisparvovec-hopf), the first treatment for pediatric patients with MPS IIIA, also known as Sanfilippo syndrome type A. The coverage outlines how the one-time gene therapy works, the clinical evidence behind its approval, and what it means for families affected by the rare, progressively degenerative disease.

The report details the therapy's use of an AAV9 viral vector to deliver a working copy of the SGSH gene, restoring production of the sulfamidase enzyme, and summarizes clinical study results showing that treated children ages 2 to 5 maintained or improved cognitive function compared with an untreated historical control group. It also covers statements from FDA officials describing the approval as a milestone for gene therapy in rare pediatric diseases.

Stonebridge Herald's reporting further addresses the therapy's safety profile, including warnings for thrombotic microangiopathy and potential long-term tumor risk, as well as the administration protocol involving corticosteroid treatment before and after infusion. The article notes that approval was granted to Ultragenyx Pharmaceutical, Inc., following prior Orphan Drug, Fast Track, and Breakthrough Therapy designations.

The full report, including additional context on the FDA's review process for gene therapies and related recent approvals, is available from Stonebridge Herald.